Introduction {#sec1}
============

Besides a class of homonuclear N-heterocyclic compounds, their N-fused hybrid structures frequently exhibit characteristic biological activities that are not shown in each homonuclear scaffold. Thus, many synthetic methods for such hybrid structures have been developed and tested for biological activities.^[@ref1]^ It is known that benzimidazole-fused pyrimidines, benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidines, also exhibit diverse biological activities and fluorescent properties ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, **A**).^[@ref2]−[@ref4]^ However, in contrast to the well-known synthetic methods and biological activities for benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidines, those for benzo\[4,5\]imidazo\[1,2-*c*\]pyrimidines are relatively rare ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, **B**). It is reported that such a scaffold can be synthesized by the initial addition of 2-cyanomethylbenzimidazole to trichloroacetonitrile and the condensation of the resulting adduct with ethyl orthoformate.^[@ref5]^ Goekjian and co-workers have demonstrated that a series of functionalized benzo\[4,5\]imidazo\[1,2-*c*\]pyrimidines can also be prepared by aza-Graebe--Ullmann coupling and palladium-catalyzed Buchwald--Hartwig coupling protocols starting from 4,6-dichloropyrimidine and benzotriazole, thus showing activity against anaplastic lymphoma kinase.^[@ref6]^ The course of our continuing studies aiming to develop a new protocol for transition-metal-catalyzed coupling and cyclization reactions led us to seek for a new synthetic method for benzo\[4,5\]imidazo\[1,2-*c*\]pyrimidines.^[@ref7]^ This report describes copper-catalyzed coupling and cyclization of 2-(2-bromovinyl)benzimidazoles with cyanamide, leading to a class of benzo\[4,5\]imidazo\[1,2-*c*\]pyrimidines under microwave irradiation ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}).^[@ref8],[@ref9]^ To the best of our knowledge, two reports are found for the synthesis of N-fused hybrid scaffolds using cyanamide. Fu et al. have shown that 2-bromo-*N*-(2-halophenyl)benzamides and *N*-(2-halophenyl)propiolamides are coupled and cyclized with cyanamide in the presence of a copper catalyst along with a ligand to form benzimidazo\[2,1-*b*\]quinazolin-12(6*H*)-ones and benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidin-4(10*H*)-ones, respectively ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}).^[@ref10]^ The present work shows another example for the synthesis of N-fused hybrid scaffolds using cyanamide.
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Results and Discussion {#sec2}
======================

Treatment of 2-(2-bromocyclohex-1-en-1-yl)-1*H*-benzo\[*d*\]imidazole (**1a**) with 2 equiv of cyanamide (**2**) in dimethylformamide (DMF) in the presence of a catalytic amount of CuI (10 mol %) and K~2~CO~3~ at 100 °C for 30 min under microwave irradiation (100 W of initial power) afforded 1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-6-amine (**3a**) in 51% yield ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 1) with incomplete conversion of **1a**. Prolonging the reaction time up to 1 h was needed for the effective formation of **3a** with complete conversion of **1a**; however, the reaction was accompanied by several unidentifiable side products ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 2).[a](#fn1){ref-type="fn"}^,^[b](#fn2){ref-type="fn"} The reaction temperature was also critical for the effective formation of **3a**, and the yield raised with the increase in temperature up to 100 °C ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 2--4, 14, and 16). When used with K~2~CO~3~ as a base and DMF as a solvent, copper salts such as CuCl, CuBr, and Cu(OAc)~2~·H~2~O showed lower catalytic activities than did CuI ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 5--7). Performing the reaction using copper powder combined with [l]{.smallcaps}-proline and copper powder resulted in lower yield of **3a** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 8 and 9).[c](#fn3){ref-type="fn"} The reaction also proceeded in the presence of other bases such as NaOAc, KOH, NaO^*t*^Bu, and Cs~2~CO~3~ in combination with CuI and DMF, but the yield of **3a** was lower than that when K~2~CO~3~ was employed ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 10--13). However, an activity similar to that of K~2~CO~3~ was observed with K~3~PO~4~ ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 14). Here again, further addition of [l]{.smallcaps}-proline gave no change in the yield of **3a** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 15). Among the solvents examined in combination with CuI and K~3~PO~4~, DMF was found to be of choice ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 14 and 17--19). No expected product was observed in the absence of copper catalyst, and **1a** was recovered almost completely ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 20--23).

###### Optimization of Conditions for the Reaction of **1a** and **2**[a](#t1fn1){ref-type="table-fn"}

![](ao-2017-00693g_0006){#GRAPHIC-d120e461-autogenerated}

  entry                                Cu catalyst        base         solvent       temp (°C)   yield[b](#t1fn2){ref-type="table-fn"} (%)
  ------------------------------------ ------------------ ------------ ------------- ----------- -------------------------------------------
  1[c](#t1fn3){ref-type="table-fn"}    CuI                K~2~CO~3~    DMF           100         51
  2                                    CuI                K~2~CO~3~    DMF           100         77
  3                                    CuI                K~2~CO~3~    DMF           80          62
  4                                    CuI                K~2~CO~3~    DMF           120         76
  5                                    CuCl               K~2~CO~3~    DMF           100         54
  6                                    CuBr               K~2~CO~3~    DMF           100         65
  7                                    Cu(OAc)~2~·H~2~O   K~2~CO~3~    DMF           100         57
  8                                    Cu powder          K~2~CO~3~    DMF           100         47
  9[d](#t1fn4){ref-type="table-fn"}    Cu powder          K~2~CO~3~    DMF           100         49
  10                                   CuI                NaOAc        DMF           100         54
  11                                   CuI                KOH          DMF           100         63
  12                                   CuI                NaO^*t*^Bu   DMF           100         71
  13                                   CuI                Cs~2~CO~3~   DMF           100         44
  14                                   CuI                K~3~PO~4~    DMF           100         79
  15[d](#t1fn4){ref-type="table-fn"}   CuI                K~3~PO~4~    DMF           100         79
  16                                   CuI                K~3~PO~4~    DMF           120         78
  17                                   CuI                K~3~PO~4~    DMSO          100         73
  18                                   CuI                K~3~PO~4~    1,4-dioxane   100         26
  19                                   CuI                K~3~PO~4~    toluene       100         38
  20                                                      K~3~PO~4~    DMF           100         0
  21                                                      K~2~CO~3~    DMF           100         0
  22                                                      KOH          DMF           100         0
  23                                                      NaO^*t*^Bu   DMF           100         0

Reaction conditions: **1a** (0.3 mmol), **2a** (0.6 mmol), Cu catalyst (0.03 mmol), base (0.6 mmol), solvent (3 mL), under microwave irradiation (100 W of initial power), 1 h, unless otherwise stated.

Isolated yield.

Reaction time: 30 min.

In the presence of [l]{.smallcaps}-proline (0.12 mmol).

After the reaction conditions had been optimized, various 2-(2-bromovinyl)benzimidazoles **1** were subjected to the reaction with cyanamide **2** to investigate the reaction scope, and several representative results are summarized in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}. The six-membered 2-(2-bromovinyl)benzimidazoles (**1b** and **1c**) reacted with **2** to give the corresponding benzo\[4,5\]imidazo\[1,2-*c*\]pyrimidin-1-amines (**3b** and **3c**), irrespective of the presence of the methyl and phenyl substituents on **1b** and **1c**. The coupling and cyclization with **1d** having a dimethyl substituent on the benzimidazole moiety also proceeded to give the corresponding benzo\[4,5\]imidazo\[1,2-*c*\]pyrimidin-1-amine **3d**. With cyclic 2-(2-bromovinyl)benzimidazoles **1e--h** having various ring sizes, the corresponding coupled and cyclized products, benzo\[4,5\]imidazo\[1,2-*c*\]pyrimidin-1-amines **3e--h**, were also formed, as expected, in the range of 57--83% yields. Lower reaction yield, not yet explained, was observed with **1e**. For testing the effect of the position of bromide and benzimidazole groups on benzo-fused 2-(2-bromovinyl)benzimidazoles, **1i** and **1j** were employed. The coupling and cyclization took place irrespective of the position, and both cases are accompanied by the dehydrogenation of benzo\[4,5\]imidazo\[1,2-*c*\]pyrimidin-1-amines initially formed by the coupling and cyclization of **1i** and **1j** with **2** under the employed conditions. The coupling and cyclization product **3i** formed from **1i** was partially dehydrogenated to **3i′**, whereas the product from **1j** was completely dehydrogenated to **3j**. Such a similar dehydrogenation was observed by our recent reports on copper-catalyzed coupling and cyclization of β-bromo-α,β-unsaturated carboxylic acids with terminal alkynes and palladium-catalyzed carbonylative cyclization of 2-(2-bromovinyl)benzimidazoles.^[@ref12]^ The reaction of acyclic 2-(2-bromovinyl)benzimidazole **1k** with **2** also afforded the coupled and cyclized product **3k**; however, the yield was lower than that when cyclic 2-(2-bromovinyl)benzimidazoles were used. Similar treatment of 2-(2-bromoaryl)benzimidazoles **1l--n** and 2-(2-bromoaryl)imidazole **1o** with **2** under the employed conditions also afforded the coupling and cyclization products **3l--o** in 69--85% yields. It is known that benzimidazole- and imidazole-fused quinazolines, benzo\[4,5\]imidazo\[1,2-*c*\]quinazolines and imidazo\[1,2-*c*\]quinazolines, have a wide spectrum of biological activities and act as commercial drugs.^[@ref13]^

###### Scope of Coupling and Cyclization Reaction[a](#t2fn1){ref-type="table-fn"}

![](ao-2017-00693g_0007){#gr6}

Reaction conditions: **1** or **4a** (0.3 mmol), **2** (0.6 mmol), CuI (0.03 mmol), K~3~PO~4~ (0.6 mmol), DMF (3 mL), 100 °C (with **1**), 130 °C (with **4**), 1 h, under microwave irradiation (100 W of initial power).

The present protocol can be extended to the reaction with 2-(2-bromophenyl)-1*H*-indoles **4** ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). Similar treatment of 2-(2-bromophenyl)-1*H*-indole (**4a**) with **2** under the optimized conditions shown in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} produced indolo\[1,2-*c*\]quinazolin-6-amine (**5a**) in 47% yield. However, further tuning with the reaction temperature resulted in an increased yield of **5a** (73% yield at 130 °C). From the reaction of several 2-(2-bromophenyl)-1*H*-indoles **4b--d** with **2**, the corresponding coupled and cyclized indolo\[1,2-*c*\]quinazolin-6-amines **5b--d** were also invariably produced irrespective of straight and branched alkyl chains on the indole moiety. It is also known that indole-fused quinazolines, indolo\[1,2-*c*\]quinazolines, exhibit biological activities such as antibacterial and antifungal properties.^[@ref14]^

Although no additional experimental efforts for the reaction pathway were performed, the reaction seems to proceed via an initial formation of intermediate **6** by copper-catalyzed Ullmann-type coupling between **1** (or **4**) and **2** ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}).^[@ref15]^ This is followed by the intramolecular addition of N--H to CN to form **7**, which triggers tautomerization to give product **3**. The following experimental observation is worth noting as evidence for the formation of intermediate **6**. We confirmed that a similar treatment of 2-(2-bromophenyl)-1-methyl-1*H*-benzo\[*d*\]imidazole (**8**) with **2** under the employed conditions afforded C--N-coupled product **9** in 78% yield ([Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}, see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00693/suppl_file/ao7b00693_si_001.pdf)). A similar pathway has already been proposed in copper-catalyzed coupling and cyclization reactions using cyanamide.^[@ref10],[@ref16]^

![Reaction Pathway](ao-2017-00693g_0004){#sch4}

![Experiment for Mechanism Study](ao-2017-00693g_0005){#sch5}

Conclusions {#sec3}
===========

It has been shown that 2-(2-bromovinyl)benzimidazoles and their analogs are coupled and cyclized with cyanamide under microwave irradiation in the presence of CuI to give a class of N-fused hybrid scaffolds, benzo\[4,5\]imidazo\[1,2-*c*\]pyrimidin-1-amines and their analogs. The present reaction provides a new method for synthesizing several N-fused hybrid heterocycles from readily available starting compounds.

Experimental Section {#sec4}
====================

General Information {#sec4-1}
-------------------

^1^H and ^13^C NMR spectra were recorded at 500 and 125 MHz, respectively, in DMSO-*d*~6~ or CDCl~3~. Melting points were determined on a microscopic melting point apparatus. High-resolution mass data were recorded using electron ionization (HRMS-EI, magnetic sector-electric sector double-focusing mass analyzer) at the Korea Basic Science Center, Daegu, Korea. All microwave reactions (CEM, Discover LabMate) were carried out in a sealed tube (5 mL), and the reaction temperature was maintained by an external infrared sensor. The isolation of pure products was carried out via thin-layer (a glass plate coated with Kieselgel 60 GF~254~, Merck) chromatography (TLC). The starting 2-(2-bromovinyl)benzimidazoles and their analogs were prepared by literature procedures.^[@ref17]−[@ref19]^ Commercially available organic and inorganic compounds were used without further purification.

General Procedure for the Synthesis of **3** {#sec4-2}
--------------------------------------------

A 10 mL microwave reaction tube was charged with **1** (0.3 mmol) and **2** (0.025 g, 0.6 mmol) together with CuI (0.006 g, 0.03 mmol), K~3~PO~4~ (0.127 g, 0.6 mmol), and DMF (3 mL). The reaction mixture was heated to 100 °C for 1 h by microwave irradiation at 100 W initial power. The mixture was then cooled to room temperature and filtered through a short silica gel column (ethyl acetate) to remove inorganic components. Removal of the solvent left a crude mixture that was separated by TLC (dichloromethane/MeOH = 19:1) to give **3**. Except for known **3l**,^[@ref20]^ all new products were characterized spectroscopically.

### 1,2,3,4-Tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-6-amine (**3a**) {#sec4-2-1}

White solid (56 mg, 79%). mp 251--253 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.78--1.84 (m, 4H), 2.61--2.63 (m, 2H), 2.76--2.78 (m, 2H), 7.27--7.30 (m, 3H), 7.44--7.47 (m, 1H), 7.73 (d, *J* = 8.0 Hz, 1H), 8.33 (d, *J* = 8.3 Hz, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 21.9, 22.5, 30.9, 106.8, 114.3, 118.1, 120.5, 125.2, 127.2, 144.8, 147.0, 150.7, 151.5. HRMS (EI) anal. calcd for C~14~H~14~N~4~ (M^+^): 238.1218. Found: 238.1218.

### 2-Methyl-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-6-amine (**3b**) {#sec4-2-2}

White solid (58 mg, 77%). mp 264--266 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.09 (d, *J* = 6.5 Hz, 3H), 1.42--1.50 (m, 1H), 1.86--1.97 (m, 2H), 2.26--2.31 (m, 1H), 2.61--2.72 (m, 2H), 2.95--3.00 (m, 1H), 7.27--7.30 (m, 3H), 7.44--7.47 (m, 1H), 7.71 (d, *J* = 8.0 Hz, 1H), 8.32 (d, *J* = 8.2 Hz, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 21.5, 27.9, 30.5, 30.6, 30.8, 106.3, 114.2, 118.1, 120.4, 125.1, 127.2, 144.8, 147.0, 150.7, 151.0. HRMS (EI) anal. calcd for C~15~H~16~N~4~ (M^+^): 252.1375. Found: 252.1372.

### 2-Phenyl-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-6-amine (**3c**) {#sec4-2-3}

White solid (62 mg, 66%). mp 231--233 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.97--2.07 (m, 2H), 2.68--2.73 (m, 1H), 2.76--2.87 (m, 2H), 3.02--3.06 (m, 1H), 3.14--3.18 (m, 1H), 7.22--7.25 (m, 1H), 7.28--7.37 (m, 7H), 7.44--7.47 (m, 1H), 7.71 (d, *J* = 8.1 Hz, 1H), 8.35 (d, *J* = 8.3 Hz, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 29.5, 30.3, 31.1, 38.9, 106.3, 114.3, 118.2, 120.5, 125.2, 126.2, 126.8, 127.2, 128.4, 144.8, 146.0, 147.1, 150.5, 151.0. HRMS (EI) anal. calcd for C~20~H~18~N~4~ (M^+^): 314.1531. Found: 314.1528.

### 9,10-Dimethyl-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-6-amine (**3d**) {#sec4-2-4}

White solid (51 mg, 64%). mp 243--245 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.75--1.83 (m, 4H), 2.36 (s, 3H), 2.39 (s, 3H), 2.58--2.60 (m, 2H), 2.72--2.75 (m, 2H), 7.19 (s, 2H), 7.49 (s, 1H), 8.14 (s, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 19.9, 20.0, 21.9, 22.4, 22.5, 30.8, 106.7, 114.2, 118.2, 125.5, 129.1, 133.6, 143.3, 146.7, 150.1, 150.5. HRMS (EI) anal. calcd for C~16~H~18~N~4~ (M^+^): 266.1531. Found: 266.1531.

### 2,3-Dihydro-1*H*-benzo\[4,5\]imidazo\[1,2-*c*\]cyclopenta\[*e*\]pyrimidin-5-amine (**3e**) {#sec4-2-5}

White solid (38 mg, 57%). mp 236--238 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.10--2.16 (m, 2H), 2.83--2.86 (m, 2H), 2.97--2.99 (m, 2H), 7.28--7.31 (m, 1H), 7.43 (s, 2H), 7.45--7.48 (m, 1H), 7.70 (d, *J* = 8.1 Hz, 1H), 8.34 (d, *J* = 8.3 Hz, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 21.6, 27.6, 34.1, 109.5, 114.2, 118.1, 120.3, 125.3, 127.1, 144.9, 148.9, 149.6, 160.2. HRMS (EI) anal. calcd for C~13~H~12~N~4~ (M^+^): 224.1062. Found: 224.1060.

### 2,3,4,5-Tetrahydro-1*H*-benzo\[4,5\]imidazo\[1,2-*c*\]cyclohepta\[*e*\]pyrimidin-7-amine (**3f**) {#sec4-2-6}

White solid (63 mg, 83%). mp 257--259 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.59--1.62 (m, 4H), 1.80--1.82 (m, 2H), 2.79--2.82 (m, 2H), 3.02--3.04 (m, 2H), 7.25--7.28 (m, 1H), 7.32 (br s, 2H), 7.43--7.46 (m, 1H), 7.70 (d, *J* = 8.1 Hz, 1H), 8.34 (d, *J* = 8.3 Hz, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 25.3, 25.7, 27.1, 32.0, 37.3, 111.5, 114.3, 117.8, 120.0, 125.2, 127.4, 144.9, 146.8, 151.4, 157.3. HRMS (EI) anal. calcd for C~15~H~16~N~4~ (M^+^): 252.1375. Found: 252.1373.

### 1,2,3,4,5,6-Hexahydrobenzo\[4,5\]imidazo\[1,2-*c*\]cycloocta\[*e*\]pyrimidin-8-amine (**3g**) {#sec4-2-7}

White solid (64 mg, 80%). mp 251--252 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.33--1.41 (m, 4H), 1.64--1.73 (m, 4H), 2.73--2.75 (m, 2H), 2.97--3.00 (m, 2H), 7.26--7.29 (m, 1H), 7.32 (br s, 2H), 7.44--7.47 (m, 1H), 7.73 (d, *J* = 8.1 Hz, 1H), 8.34 (d, *J* = 8.3 Hz, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 24.4, 25.6, 26.1, 29.5, 29.7, 32.6, 109.6, 114.2, 118.0, 120.2, 125.2, 127.3, 145.0, 147.5, 150.8, 154.3. HRMS (EI) anal. calcd for C~16~H~18~N~4~ (M^+^): 266.1531. Found: 266.1531.

### 1,2,3,4,5,6,7,8,9,10-Decahydrobenzo\[4,5\]imidazo\[1,2-*c*\]cyclododeca\[*e*\]pyrimidin-12-amine (**3h**) {#sec4-2-8}

White solid (75 mg, 78%). mp 240--242 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.25--1.39 (m, 8H), 1.48--1.52 (m, 4H), 1.79--1.86 (m, 4H), 2.60--2.63 (m, 2H), 2.84--2.87 (m, 2H), 7.23 (br s, 2H), 7.27--7.30 (m, 1H), 7.44--7.47 (m, 1H), 7.74 (d, *J* = 8.0 Hz, 1H), 8.32 (d, *J* = 8.2 Hz, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 21.9, 22.5, 23.7, 23.9, 25.0, 25.4, 26.4, 26.7, 30.0, 110.0, 114.3, 118.1, 120.4, 125.2, 127.0, 144.9, 146.9, 151.3, 154.1. HRMS (EI) anal. calcd for C~20~H~26~N~4~ (M^+^): 322.2157. Found: 322.2159.

### 5,6-Dihydrobenzo\[*f*\]benzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-8-amine (**3i**) {#sec4-2-9}

White solid (48 mg, 56%). mp 227--228 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.85--2.89 (m, 2H), 2.93--2.96 (m, 2H), 7.16--7.19 (m, 1H), 7.26 (d, *J* = 7.3 Hz, 1H), 7.32--7.37 (m, 2H), 7.51--7.54 (m, 1H), 7.76 (s, 2H), 7.85 (d, *J* = 7.8 Hz, 1H), 8.41 (d, *J* = 8.3 Hz, 1H), 9.09 (dd, *J* = 7.9 and 1.0 Hz, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 30.5, 30.7, 105.0, 114.2, 118.4, 120.9, 125.6, 125.8, 126.1, 126.2, 126.4, 127.3, 131.4, 134.5, 144.9, 148.2, 148.3, 154.9. HRMS (EI) anal. calcd for C~18~H~14~N~4~ (M^+^): 286.1218. Found: 286.1219.

### Benzo\[*f*\]benzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-8-amine (**3i′**) {#sec4-2-10}

White solid (24 mg, 28%). mp 236--238 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 7.48--7.51 (m, 1H), 7.59--7.63 (m, 2H), 7.65 (d, *J* = 8.9 Hz, 1H), 7.67 (br s, 2H), 7.81--7.84 (m, 1H), 8.05 (d, *J* = 8.1 Hz, 2H), 8.16 (d, *J* = 8.8 Hz, 1H), 8.52 (d, *J* = 8.3 Hz, 1H), 10.34 (d, *J* = 8.6 Hz, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 107.2, 114.4, 119.0, 122.2, 124.9, 125.0, 125.4, 126.4, 126.8, 127.9, 128.5, 129.5, 129.9, 132.7, 144.2, 145.7, 147.5, 148.7. HRMS (EI) anal. calcd for C~18~H~12~N~4~ (M^+^): 284.1062. Found: 284.1060.

### Benzo\[*h*\]benzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-8-amine (**3j**) {#sec4-2-11}

White solid (66 mg, 77%). mp 233--236 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 7.41--7.44 (m, 1H), 7.52--7.56 (m, 2H), 7.58 (d, *J* = 8.8 Hz, 1H), 7.60 (br s, 2H), 7.74--7.77 (m, 1H), 7.97--7.99 (m, 2H), 8.09 (d, *J* = 8.8 Hz, 1H), 8.34 (d, *J* = 8.3 Hz, 1H), 9.97 (d, *J* = 8.6 Hz, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 106.8, 114.5, 119.1, 122.3, 125.1, 125.2, 125.6, 126.3, 126.7, 127.8, 128.6, 129.5, 130.2, 132.6, 144.1, 145.6, 147.5, 149.5. HRMS (EI) anal. calcd for C~18~H~12~N~4~ (M^+^): 284.1062. Found: 284.1060.

### 4-Methyl-3-phenylbenzo\[4,5\]imidazo\[1,2-*c*\]pyrimidin-1-amine (**3k**) {#sec4-2-12}

White solid (42 mg, 51%). mp 276--278 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.40 (s, 3H), 7.20--7.22 (m, 2H), 7.48--7.51 (m, 1H), 7.54--7.56 (m, 2H), 7.60 (br s, 2H), 7.95 (d, *J* = 8.3 Hz, 2H), 8.16--8.18 (m, 2H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 14.7, 114.6, 114.9, 120.5, 121.4, 125.8, 127.7, 128.6, 129.3, 130.2, 131.0, 131.7, 145.0, 146.3, 151.3. HRMS (EI) anal. calcd for C~17~H~14~N~4~ (M^+^): 274.1218. Found: 274.1220.

### Benzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-6-amine (**3l**) {#sec4-2-13}

White solid (60 mg, 85%). mp \> 300 °C (lit.^[@ref20]^ mp \> 300 °C). ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 7.35--7.38 (m, 1H), 7.42--7.46 (m, 3H), 7.51--7.55 (m, 2H), 7.63--7.67 (m, 1H), 7.91 (d, *J* = 8.0 Hz, 1H), 8.40 (dd, *J* = 7.8 and 0.8 Hz, 1H), 8.43 (d, *J* = 8.3 Hz, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 114.3, 114.7, 119.1, 122.3, 123.1, 123.8, 124.3, 125.0, 128.2, 131.8, 143.9, 144.6, 146.5, 148.4.

### 9,10-Dimethylbenzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-6-amine (**3m**) {#sec4-2-14}

White solid (55 mg, 70%). mp 271--273 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.40 (s, 3H), 2.44 (s, 3H), 7.32--7.35 (m, 1H), 7.38 (br s, 2H), 7.48 (d, *J* = 8.2 Hz, 1H), 7.60--7.63 (m, 1H), 7.66 (s, 1H), 8.24 (s, 1H), 8.34 (d, *J* = 7.9 Hz, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 20.0, 20.1, 114.3, 114.8, 119.0, 123.0, 123.6, 124.3, 126.5, 131.3, 131.4, 133.8, 142.4, 144.5, 146.4, 147.7. HRMS (EI) anal. calcd for C~16~H~14~N~4~ (M^+^): 262.1218. Found: 262.1215.

### 8,11-Dimethoxybenzo\[4,5\]imidazo\[1,2-*c*\]quinazolin-6-amine (**3n**) {#sec4-2-15}

White solid (61 mg, 69%). mp 285--287 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 3.97 (s, 3H), 4.07 (s, 3H), 7.01 (d, *J* = 8.8 Hz, 1H), 7.07 (d, *J* = 8.8 Hz, 1H), 7.29--7.32 (m, 1H), 7.43 (d, *J* = 7.8 Hz, 1H), 7.59--7.62 (m, 1H), 8.31 (br s, 2H), 8.35--8.36 (m, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 55.9, 57.9, 106.3, 106.4, 114.2, 119.1, 122.6, 123.7, 123.8, 131.7, 136.0, 139.0, 144.7, 145.4, 146.0, 148.0. HRMS (EI) anal. calcd for C~16~H~14~N~4~O~2~ (M^+^): 294.1117. Found: 294.1120.

### 2,3-Diphenylimidazo\[1,2-*c*\]quinazolin-5-amine (**3o**) {#sec4-2-16}

White solid (70 mg, 69%). mp 289--292 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 6.04 (br s, 2H), 7.23--7.29 (m, 3H), 7.35--7.38 (m, 1H), 7.46--7.51 (m, 3H), 7.55--7.59 (m, 1H), 7.60--7.70 (m, 5H), 8.36 (dd, *J* = 7.9 and 1.2 Hz, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 115.5, 121.2, 122.3, 123.3, 124.2, 127.2, 127.5, 128.2, 129.2, 130.1, 130.2, 130.3, 132.1, 133.5, 140.4, 142.5, 143.8, 144.6. HRMS (EI) anal. calcd for C~22~H~16~N~4~ (M^+^): 336.1375. Found: 336.1373.

### Indolo\[1,2-*c*\]quinazolin-6-amine (**5a**) {#sec4-2-17}

Pale yellow solid (51 mg, 73%). mp 249--252 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 7.13 (br s, 2H), 7.17--7.24 (m, 1H), 7.29--7.44 (m, 5H), 7.79 (d, *J* = 7.4 Hz, 1H), 8.10 (dd. *J* = 7.8 and 1.0 Hz, 1H), 8.38 (d, *J* = 8.1 Hz, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 95.8, 113.4, 118.0, 121.0, 122.1, 122.9, 123.6, 124.0, 124.4, 129.3, 130.7, 130.9, 136.1, 140.4, 146.6. HRMS (EI) anal. calcd for C~15~H~11~N~3~ (M^+^): 233.0953. Found: 233.0951.

### 12-Methylindolo\[1,2-*c*\]quinazolin-6-amine (**5b**) {#sec4-2-18}

Pale yellow solid (44 mg, 59%). mp 217--219 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.73 (s, 3H), 7.01 (s, 2H), 7.24--7.27 (m, 1H), 7.35--2.44 (m, 4H), 7.86 (d, *J* = 7.8 Hz, 1H), 8.18 (d, *J* = 8.0 Hz, 1H), 8.32 (d, *J* = 8.5 Hz, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 10.9, 106.9, 113.4, 118.9, 119.8, 122.4, 123.1, 123.7, 123.8, 124.2, 128.4, 129.5, 130.6, 131.8, 140.9, 146.9. HRMS (EI) anal. calcd for C~16~H~13~N~3~ (M^+^): 247.1109. Found: 247.1108.

### 12-Butylindolo\[1,2-*c*\]quinazolin-6-amine (**5c**) {#sec4-2-19}

Pale yellow solid (48 mg, 55%). mp 204--205 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 0.95 (t, *J* = 7.4 Hz, 3H), 1.44--1.51 (m, 2H), 1.65--1.71 (m, 2H), 3.23 (t, *J* = 7.6 Hz, 2H), 7.00 (br s, 2H), 7.26--7.28 (m, 1H), 7.35--7.38 (m, 2H), 7.40--7.43 (m, 2H), 7.83 (d, *J* = 7.8 Hz, 1H), 8.10 (d, *J* = 7.9 Hz, 1H), 8.32 (d, *J* = 8.3 Hz, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 14.1, 23.0, 24.8, 31.7, 112.6, 113.5, 118.9, 119.5, 122.4, 123.0, 123.6, 123.7, 124.5, 128.4, 129.6, 130.2, 131.6, 141.2, 147.0. HRMS (EI) anal. calcd for C~19~H~19~N~3~ (M^+^): 289.1579. Found: 289.1580.

### 12-Isopropylindolo\[1,2-*c*\]quinazolin-6-amine (**5d**) {#sec4-2-20}

Pale yellow solid (45 mg, 54%). mp 184--186 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.57 (d, *J* = 7.1 Hz, 6H), 4.09 (sep, *J* = 7.1 Hz, 1H), 6.95 (s, 2H), 7.22--7.25 (m, 1H), 7.32--7.42 (m, 4H), 8.04 (d, *J* = 7.6 Hz, 1H), 8.16 (d, *J* = 8.0 Hz, 1H), 8.32 (d, *J* = 8.0 Hz, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 22.2, 26.5, 113.9, 118.6, 119.4, 121.4, 122.1, 122.7, 123.5, 124.0, 124.4, 128.5, 129.5, 129.9, 130.6, 141.6, 147.1. HRMS (EI) anal. calcd for C~18~H~17~N~3~ (M^+^): 275.1422. Found: 275.1420.
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The yield of **3a** was considerably affected by the molar ratio of **2** to **1a**. The yield gradually increased from 47% (\[**2**\]/\[**1a**\] = 1.0), to 60% (\[**2**\]/\[**1a**\] = 1.5), and to 77% (\[**2**\]/\[**1a**\] = 2.0).

Similar treatment of **1a** (0.3 mmol) with **2** (0.6 mmol) in DMF (3 mL) in the presence of CuI (0.03 mmol) and K~2~CO~3~ (0.6 mmol) under usual heating method (screw-capped vial, 100 °C for 24 h) afforded **3a** in 49% yield with 68% conversion of **1a**.

It is known that Cu catalyst combined with amino acid effectively catalyzes C--N cross-coupling reactions. See ref ([@ref11]).
